The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.
1. An optionally N-oxidized compound represented by the formula:
wherein
Z n is a bond,
W n is a bond,
R 1n in is a hydrogen atom, a hydrocarbon group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an amino group optionally having substituent(s) or an acyl group,
R 2n is an aromatic group optionally having substituent (s), and
R 3n is a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent (s) or a prodrug thereof.
2. An optionally N-oxidized compound represented by the formula:
wherein
R 1g is a hydrogen atom, a hydrocarbon group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an amino group optionally having substituent(s) or an acyl group,
R 2g is an aromatic group optionally having substituent (s),
R 3g is a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s), and
R 4g is a hydrogen atom or a hydrocarbon group optionally having substituent (s) or a prodrug thereof.
3. A prodrug of the compound of claim 1 .
4. A pharmaceutical agent containing a compound of claim 1 or a prodrug thereof.
5. A prodrug of the compound of claim 2 .
6. A pharmaceutical agent containing a compound of claim 2 or a prodrug thereof.